LIFECORE BIOMEDICAL, INC. Loss Contingency, Estimate of Possible Loss
LIFECORE BIOMEDICAL, INC. (LFCR) had Loss Contingency, Estimate of Possible Loss of $1.80 million as of 2020-11-29, per its 10-Q filed 2021-01-07.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2021-10-05
- 2020-11-29: Loss Contingency, Estimate of Possible Loss $1.80M.
- 2020-11-03: Loss Contingency, Estimate of Possible Loss $80.00M.
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2020-11-29 | $1.80M 10-Q · filed 2021-01-07 |
| 2020-11-03 | $80.00M 10-Q · filed 2021-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |